Cerecor, Inc. logo

Cerecor, Inc.

Cerecor (NASDAQ:CERC) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system.

Cerecor was led by Blake Paterson, the founder & former CEO at Alba Therapeutics. The chairman is former Celgene CEO Sol Barer, who recently packaged four biotechs into a single drug developer, RestorGenex.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”CERC” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cerecor.com
Disease Focus
STOCK CODENASDAQ: CERC
Address
400 East Pratt Street Suite 606, MD 21202
Baltimore
United States
Email
Contact Number
+1 410-522-8707

Cerecor (NASDAQ:CERC) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system.

Cerecor was led by Blake Paterson, the founder & former CEO at Alba Therapeutics. The chairman is former Celgene CEO Sol Barer, who recently packaged four biotechs into a single drug developer, RestorGenex.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cerecor-inc-” connections=”true” suffix=””]

Cerecor has developed a COMT (catechol-O-methyl transferase) Inhibitor Platform which aids in developing different compounds for different disease states.

In Feb, 2015, Cerecor acquired Phase 2-ready Kappa Opioid Receptor Antagonist indicating for depression & co-occurring substance use disorders, such as alcohol, or illicit drug addiction from Eli Lilly & Co. Financial details were not disclosed.

In Apr 2013, Merck granted Cerecor exclusive, worldwide rights to develop and commercialize Mercks MK-0657 (CERC-301) for all indications. Financial details were not disclosed.

In Sep 2016, Cerecor acquired worldwide license of CERC-611 from Lilly, and, any product containing CERC-611 for the prevention, diagnosis and/or treatment of human diseases. Lilly to receive upfront licensing fee as well as milestone and tiered royalty payments on net sales.